» Articles » PMID: 34001250

The Attributes of Plakins in Cancer and Disease: Perspectives on Ovarian Cancer Progression, Chemoresistance and Recurrence

Overview
Publisher Biomed Central
Date 2021 May 18
PMID 34001250
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The plakin family of cytoskeletal proteins play an important role in cancer progression yet are under-studied in cancer, especially ovarian cancer. These large cytoskeletal proteins have primary roles in the maintenance of cytoskeletal integrity but are also associated with scaffolds of intermediate filaments and hemidesmosomal adhesion complexes mediating signalling pathways that regulate cellular growth, migration, invasion and differentiation as well as stress response. Abnormalities of plakins, and the closely related spectraplakins, result in diseases of the skin, striated muscle and nervous tissue. Their prevalence in epithelial cells suggests that plakins may play a role in epithelial ovarian cancer progression and recurrence. In this review article, we explore the roles of plakins, particularly plectin, periplakin and envoplakin in disease-states and cancers with emphasis on ovarian cancer. We discuss the potential role the plakin family of proteins play in regulating cancer cell growth, survival, migration, invasion and drug resistance. We highlight potential relationships between plakins, epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) and discuss how interaction of these processes may affect ovarian cancer progression, chemoresistance and ultimately recurrence. We propose that molecular changes in the expression of plakins leads to the transition of benign ovarian tumours to carcinomas, as well as floating cellular aggregates (commonly known as spheroids) in the ascites microenvironment, which may contribute to the sustenance and progression of the disease. In this review, attempts have been made to understand the crucial changes in plakin expression in relation to progression and recurrence of ovarian cancer. Video Abstract.

Citing Articles

Plectin, a novel regulator in migration, invasion and adhesion of ovarian cancer.

Bai L, Qian X, Zhang H, Yuan Y, Cui X, Cheng M Cell Biosci. 2025; 15(1):15.

PMID: 39915800 PMC: 11804098. DOI: 10.1186/s13578-025-01349-2.


Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets.

Wesley T, Escalona R, Kannourakis G, Ahmed N Cancers (Basel). 2024; 16(23).

PMID: 39682273 PMC: 11639978. DOI: 10.3390/cancers16234087.


The combined signatures of programmed cell death and immune landscape provide a prognostic and therapeutic biomarker in the hepatocellular carcinoma.

Liu W, Huang Y, Xu Y, Gao X, Zhao Y, Fan S Front Chem. 2024; 12:1484310.

PMID: 39600313 PMC: 11591233. DOI: 10.3389/fchem.2024.1484310.


Plectin: Dual Participation in Tumor Progression.

Wang Z, Wang W, Luo Q, Song G Biomolecules. 2024; 14(9).

PMID: 39334817 PMC: 11430127. DOI: 10.3390/biom14091050.


Epiplakin expression dynamics during colon carcinogenesis: Correlation with proliferation.

Findik D, Sahin E, Turelik O, Guneri G Biomol Biomed. 2024; 25(1):62-70.

PMID: 39052015 PMC: 11647249. DOI: 10.17305/bb.2024.10981.


References
1.
Lorch J, Thomas T, Schmoll H . Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res. 2007; 67(2):727-34. DOI: 10.1158/0008-5472.CAN-06-2162. View

2.
Alkema N, Wisman G, van der Zee A, van Vugt M, de Jong S . Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resist Updat. 2016; 24:55-69. DOI: 10.1016/j.drup.2015.11.005. View

3.
Niwa T, Saito H, Imajoh-Ohmi S, Kaminishi M, Seto Y, Miki Y . BRCA2 interacts with the cytoskeletal linker protein plectin to form a complex controlling centrosome localization. Cancer Sci. 2009; 100(11):2115-25. PMC: 11158164. DOI: 10.1111/j.1349-7006.2009.01282.x. View

4.
Strauss R, Li Z, Liu Y, Beyer I, Persson J, Sova P . Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 2011; 6(1):e16186. PMC: 3021543. DOI: 10.1371/journal.pone.0016186. View

5.
Bilandzic M, Chu S, Wang Y, Tan H, Fuller P, Findlay J . Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells. Mol Endocrinol. 2013; 27(3):466-79. PMC: 5416929. DOI: 10.1210/me.2012-1239. View